Purpose:To evaluate the efficacy and toxicity of combination of MabThera and CEOP regimen in the treatment of aggressive B-cell lymphoma. Methods:21 patients diagnosed as aggressive B-cell lymphoma with median age of 48 years old (from 15 to 68 years old),received the treatment of MabThera plus CEOP regimen. This treatment consisted of MabThera 375 mg/m2 intravenously infusion on day 1,cyclophosphamide 750 mg/m 2 ,epirubicin 60 mg/m 2 ,vincristine 2 mg on day3 ,prednisone 40 mg/m 2 orally taken on day 3～7. Results:In all 21 patients,16 (76.2%) complete response and 3 (14.2%) partial response were observed. Thus,the overall response rate was 90.5%. Moreover,of the remaining patients,1(4.8%) achieved stable disease and 1(4.8%) had progressive disease. In the 19 responsive patients,the follow-up duration were from 2 to 15 months. One case of thyroid lymphoma experienced recurrence after 14 months with complete response. Until now,the other responses have been maintained. Only one dose of MabThera infusion related-toxicity was observed in all who received 87 cycles. The hematological toxicities were mainly leucopenia and neutropenia. 5( 23.8% ) experienced 3-4 grade neutropenia. Only 1 patient developed neutropenia fever. The other non-hematological toxicities were 1-2 grade except grade 3 alopecia. Conclusions:The combination of MabThera and CEOP regimen had high efficacy with mild toxicity in the treatment of aggressive B-cell lymphoma,hopefully may become the standard treatment.

ObjectiveTo evaluate the therapeutic effect and toxicities of gemcitabine combined with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma (TCC) of urinary tract. Methods Eighteen patients with advanced or metastatic TCC of urinary tract (15 cases of bladder TCC,2 of renal pelvic TCC,and 1 of ureteral TCC),who were pathologically confirmed,were treated with GC regimen (gemcitabine 1000 mg/m 2,iv infusion on day 1 and day 8;cisplatin 30 mg/m 2,iv infusion on day 2,day 8 and day 9).Before treatment, Karnofsy score for each patient was evaluated with a result of ≥60;liver and renal functions and blood routine test were normal.GC regimen was repeated for 2-3 cycles every 3-4 weeks and the response rate was evaluated.ResultsThree patients (16.7%) had complete response; 7(38.9%), partial response;5(27.8%),no response;and 3(16.7%) had progression.The overall response rate was 55.6%. The main toxic effects included decrease in white cell count (10 cases),anemia (7),nausea and vomiting (10) and constipation (8),which were mild or moderate and disappeared after stopping treatment.No chemotherapy-associated death occurred.ConclusionsGemcitabine combined with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma of urinary tract is effective,and the toxicity is mild and tolerated. It is suggested that GC regimen can be used as the first line chemotherapy.

Purpose:To investigate the efficacy and adverse effects of irinotecan, a novel and potent inhibitor of topoisomerase Ⅰ, for second line treatment of advanced colorectal cancer.Methods:14 patients who previously failed with fluorouracil treatment received single drug irinotecan 300 mg/m 2 intravenously every 3 weeks . All patients had received adjuvant therapy containing fluorouracil. Two patients had received pelvic radiotherapy.Results:Nine patients had received three cycles and five patients completed six cycles . Ten cases had stable disease, and four with progressive disease were observed among the 14 patients. The common treatment related adverse events were cholinergic syndrome (92.9%) ,delayed diarrhea (78.6%) and neutropenia (78.6%) . Grade Ⅲ side effects occurred in several patients: two nausea/ vomiting , two delayed diarrhea and one neutropenia / leucytopenia . Only one patient developed grade Ⅳ diarrhea.Conclusions: Irinotecan is an active drug in the treatment of advanced colorectal cancer with acceptable toxicity.

Ambystoma mexicanum/immunology* ; Amputation ; Animals ; Biomarkers/metabolism* ; Blastomeres/immunology* ; Cell Lineage/immunology* ; Connective Tissue Cells/immunology* ; Epithelial Cells/immunology* ; Forelimb ; Gene Expression ; High-Throughput Nucleotide Sequencing ; Humans ; Immunity ; Peroxiredoxins/immunology* ; Regeneration/immunology* ; Regenerative Medicine/methods* ; Single-Cell Analysis/methods*

Tuberous sclerosis complex(TSC)is a rare genetic disease that can lead to benign dysplasia in multiple organs such as the skin, brain, eyes, oral cavity, heart, lungs, kidneys, liver, and bones. Its main symptoms include epilepsy, intellectual disabilities, skin depigmentation, and facial angiofibromas, whilst incidence is approximately 1 in 10 000 to 1 in 6000 newborns. This case presents a middle-aged woman who initially manifested with epilepsy and nodular depigmentation. Later, she developed a lower abdominal mass, elevated creatinine, and severe anemia. Based on clinical features and whole exome sequencing, the primary diagnosis was confirmed as TSC. Laboratory and imaging examinations revealed that the lower abdominal mass originated from the uterus. CT-guided biopsy pathology and surgical pathology suggested a combination of leiomyoma and abscess. With the involvement of multiple organs and various complications beyond the main diagnosis, the diagnostic and therapeutic process for this patient highlights the importance of rigorous clinical thinking and multidisciplinary collaboration in the diagnosis and treatment of rare and challenging diseases.